Upregulation of E2F transcription factor 3 is associated with poor prognosis in hepatocellular carcinoma

Oncology Reports

Volumn 31, Issue 3, 2014, Pages 1139-1146

  Zeng, Xiaoyun ^a,b   Yin, Fuqiang ^a   Liu, Xia ^b   Xu, Jianwen ^c   Xu, Yang ^b   Huang, Jinmei ^d   Nan, Yueli ^b   Qiu, Xiaoqiang ^b  

^a Medical Scientific Research Center   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

^c GUANGXI UNIVERSITY OF CHINESE MEDICINE   (China)

^d Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention   (China)

Author keywords

Bioinformatics; E2F transcription factor 3; Hepatocellular carcinoma; Prognosis

Indexed keywords

MICRORNA; MICRORNA 103; MICRORNA 141; MICRORNA 152; MICRORNA 15A; MICRORNA 15B; MICRORNA 195; MICRORNA 200B; MICRORNA 200C; MICRORNA 30; MICRORNA 34A; TRANSCRIPTION FACTOR E2F; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BIOINFORMATICS; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; E2F3 GENE; GENE INTERACTION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC DATABASE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; UPREGULATION;

CARCINOMA, HEPATOCELLULAR; COMPUTATIONAL BIOLOGY; E2F3 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROTEIN INTERACTION MAPS; SURVIVAL ANALYSIS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84896728748     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.2968     Document Type: Article

References (75)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Singhal A, Jayaraman M, Dhanasekaran DN and Kohli V: Molecular and serum markers in hepatocellular carcinoma: predictive tools for prognosis and recurrence. Crit Rev Oncol Hematol 82: 116-140, 2012.
3. Midorikawa Y, Makuuchi M, Tang W and Aburatani H: Microarray-based analysis for hepatocellular carcinoma: from gene expression profiling to new challenges. World J Gastroenterol 13: 1487-1492, 2007. (Pubitemid 46672654)
4. Chiriva-Internati M, Grizzi F, Wachtel MS, Jenkins M, Ferrari R, Cobos E and Frezza EE: Biological treatment for liver tumor and new potential biomarkers. Dig Dis Sci 53: 836-843, 2008. (Pubitemid 351317064)
5. Hao K, Luk JM, Lee NP, Mao M, Zhang C, Ferguson MD, Lamb J, Dai H, Ng IO, Sham PC and Poon RT: Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. BMC Cancer 9: 389, 2009.
6. Chao Y, Shih YL, Chiu JH, Chau GY, Lui WY, Yang WK, Lee SD and Huang TS: Overexpression of cyclin A but not Skp 2 correlates with the tumor relapse of human hepatocellular carcinoma. Cancer Res 58: 985-990, 1998. (Pubitemid 28182468)
7. Ohashi R, Gao C, Miyazaki M, Hamazaki K, Tsuji T, Inoue Y, Uemura T, Hirai R, Shimizu N and Namba M: Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas. Anticancer Res 21: 657-662, 2001. (Pubitemid 32267589)
8. Attwooll C, Lazzerini Denchi E and Helin K: The E2F family: specific functions and overlapping interests. EMBO J 23: 4709-4716, 2004. (Pubitemid 40069701)
9. Leone G, DeGregori J, Yan Z, Jakoi L, Ishida S, Williams RS and Nevins JR: E2F3 activity is regulated during the cell cycle and is required for the induction of S phase. Genes Dev 12: 2120-2130, 1998. (Pubitemid 28348036)
10. Lees JA, Saito M, Vidal M, Valentine M, Look T, Harlow E, Dyson N and Helin K: The retinoblastoma protein binds to a family of E2F transcription factors. Mol Cell Biol 13: 7813-7825, 1993. (Pubitemid 23354306)
11. Humbert PO, Verona R, Trimarchi JM, Rogers C, Dandapani S and Lees JA: E2f3 is critical for normal cellular proliferation. Genes Dev 14: 690-703, 2000. (Pubitemid 30176823)
12. Vuaroqueaux V, Urban P, Labuhn M, Delorenzi M, Wirapati P, Benz CC, Flury R, Dieterich H, Spyratos F, Eppenberger U and Eppenberger-Castori S: Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome. Breast Cancer Res 9: R33, 2007.
13. Justenhoven C, Pierl CB, Haas S, Fischer HP, Hamann U, Baisch C, Harth V, Spickenheuer A, Rabstein S, Vollmert C, Illig T, Pesch B, Brüning T, Dippon J, Ko YD and Brauch H: Polymorphic loci of E2F2, CCND1 and CCND3 are associated with HER2 status of breast tumors. Int J Cancer 124: 2077-2081, 2009.
14. Feo F, De Miglio MR, Simile MM, Muroni MR, Calvisi DF, Frau M and Pascale RM: Hepatocellular carcinoma as a complex polygenic disease. Interpretive analysis of recent developments on genetic predisposition. Biochim Biophys Acta 1765: 126-147, 2006.
15. Ogata H, Goto S, Sato K, Fujibuchi W, Bono H and Kanehisa M: KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 27: 29-34, 1999.
16. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM: ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6: 1-6, 2004. (Pubitemid 38391943)
17. Mostafavi S, Ray D, Warde-Farley D, Grouios C and Morris Q: GeneMANIA: a real-time multiple association network integration algorithm for predicting gene function. Genome Biol 9 (Suppl 1): S4, 2008.
18. Dweep H, Sticht C, Pandey P and Gretz N: miRWalk - database: prediction of possible miRNA binding sites by 'walking' the genes of three genomes. J Biomed Inform 44: 839-847, 2011.
19. de Leeuw N, Dijkhuizen T, Hehir-Kwa JY, Carter NP, Feuk L, Firth HV, Kuhn RM, Ledbetter DH, Martin CL, van Ravenswaaij-Arts CM, Scherer SW, Shams S, Van Vooren S, Sijmons R, Swertz M and Hastings R: Diagnostic interpretation of array data using public databases and internet sources. Hum Mutat 33: 930-940, 2012.
20. Miles WO, Tschöp K, Herr A, Ji JY and Dyson NJ: Pumilio facilitates miRNA regulation of the E2F3 oncogene. Genes Dev 26: 356-368, 2012.
21. Martinez LA, Goluszko E, Chen HZ, Leone G, Post S, Lozano G, Chen Z and Chauchereau A: E2F3 is a mediator of DNA damage-induced apoptosis. Mol Cell Biol 30: 524-536, 2010.
22. Olsson AY, Feber A, Edwards S, Te Poele R, Giddings I, Merson S and Cooper CS: Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells. Oncogene 26: 1028-1037, 2007.
23. Feng B, Wang R, Song HZ and Chen LB: MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3. Cancer 118: 3365-3376, 2012.
24. 1/S transition of human hepatocellular carcinoma cells. Hepatology 50: 113-121, 2009.
25. Tryndyak VP, Ross SA, Beland FA and Pogribny IP: Down-regulation of the microRNAs miR-34a, miR-127, and miR-200b in rat liver during hepatocarcinogenesis induced by a methyl-deficient diet. Mol Carcinog 48: 479-487, 2009.
26. Foster CS, Falconer A, Dodson AR, Norman AR, Dennis N, Fletcher A, Southgate C, Dowe A, Dearnaley D, Jhavar S, Eeles R, Feber A and Cooper CS: Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 23: 5871-5879, 2004. (Pubitemid 39093531)
27. Wei LX, Zhou RS, Xu HF, Wang JY and Yuan MH: High expression of FOXC1 is associated with poor clinical outcome in non-small cell lung cancer patients. Tumour Biol 34: 941-946, 2013.
28. Wang L, Gu F, Liu CY, Wang RJ, Li J and Xu JY: High level of FOXC1 expression is associated with poor prognosis in pancreatic ductal adenocarcinoma. Tumour Biol 34: 853-858, 2013.
29. Ray PS, Bagaria SP, Wang J, Shamonki JM, Ye X, Sim MS, Steen S, Qu Y, Cui X and Giuliano AE: Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value: a retrospective immunohistochemical study. Ann Surg Oncol 18: 3839-3847, 2011.
30. Xia L, Huang W, Tian D, Zhu H, Qi X, Chen Z, Zhang Y, Hu H, Fan D, Nie Y and Wu K: Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Hepatology 57: 610-624, 2013.
31. Wang L, Wang X, Jie P, Lu H, Zhang S, Lin X, Lam EK, Cui Y, Yu J and Jin H: Klotho is silenced through promoter hypermethylation in gastric cancer. Am J Cancer Res 1: 111-119, 2011.
32. Jeschke J, Van Neste L, Glöckner SC, Dhir M, Calmon MF, Deregowski V, Van Criekinge W, Vlassenbroeck I, Koch A, Chan TA, Cope L, Hooker CM, Schuebel KE, Gabrielson E, Winterpacht A, Baylin SB, Herman JG and Ahuja N: Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. Epigenetics 7: 701-709, 2012.
33. Xie B, Zhou J, Yuan L, Ren F, Liu DC, Li Q and Shu G: Epigenetic silencing of Klotho expression correlates with poor prognosis of human hepatocellular carcinoma. Hum Pathol 44: 795-801, 2013.
34. Wang Q, Wang L, Li D, Deng J, Zhao Z, He S, Zhang Y and Tu Y: Kinesin family member 14 is a candidate prognostic marker for outcome of glioma patients. Cancer Epidemiol 37: 79-84, 2013.
35. Kim TM, Yim SH, Shin SH, Xu HD, Jung YC, Park CK, Choi JY, Park WS, Kwon MS, Fiegler H, Carter NP, Rhyu MG and Chung YJ: Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q. Int J Cancer 123: 2808-2815, 2008.
36. Xu N, Jia D, Chen W, Wang H, Liu F, Ge H, Zhu X, Song Y, Zhang X, Zhang D, Ge D and Bai C: FoxM1 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor metastasis. PLoS One 8: e59412, 2013.
37. Wang Y, Wen L, Zhao SH, Ai ZH, Guo JZ and Liu WC: FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients. Lung Cancer 79: 173-179, 2013.
38. Xia L, Mo P, Huang W, Zhang L, Wang Y, Zhu H, Tian D, Liu J, Chen Z, Zhang Y, Hu H, Fan D, Nie Y and Wu K: The TNF-α/ROS/HIF-1-induced upregulation of FoxMI expression promotes HCC proliferation and resistance to apoptosis. Carcinogenesis 33: 2250-2259, 2012.
39. Sun HC, Li M, Lu JL, Yan DW, Zhou CZ, Fan JW, Qin XB, Tang HM and Peng ZH: Overexpression of Forkhead box M1 protein associates with aggressive tumor features and poor prognosis of hepatocellular carcinoma. Oncol Rep 25: 1533-1539, 2011.
40. Agnelli L, Forcato M, Ferrari F, Tuana G, Todoerti K, Walker BA, Morgan GJ, Lombardi L, Bicciato S and Neri A: The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma. Clin Cancer Res 17: 7402-7412, 2011.
41. de Reyniès A, Assié G, Rickman DS, Tissier F, Groussin L, René-Corail F, Dousset B, Bertagna X, Clauser E and Bertherat J: Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 27: 1108-1115, 2009.
42. Liu B, Zhang J, Huang C and Liu H: Dyskerin overexpression in human hepatocellular carcinoma is associated with advanced clinical stage and poor patient prognosis. PLoS One 7: e43147, 2012.
43. Liu L, Zhang CZ, Cai M, Fu J, Chen GG and Yun J: Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis. PLoS One 7: e41293, 2012.
44. Mendler JH, Maharry K, Radmacher MD, Mrózek K, Becker H, Metzeler KH, Schwind S, Whitman SP, Khalife J, Kohlschmidt J, Nicolet D, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G and Bloomfield CD: RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures. J Clin Oncol 30: 3109-3118, 2012.
45. Buechler S: Low expression of a few genes indicates good prognosis in estrogen receptor positive breast cancer. BMC Cancer 9: 243, 2009.
46. Mamat S, Ikeda J, Tian T, Wang Y, Luo W, Aozasa K and Morii E: Transcriptional regulation of aldehyde dehydrogenase 1A1 gene by alternative spliced forms of nuclear factor Y in tumorigenic population of endometrial adenocarcinoma. Genes Cancer 2: 979-984, 2011.
47. Kong LM, Liao CG, Chen L, Yang HS, Zhang SH, Zhang Z, Bian HJ, Xing JL and Chen ZN: Promoter hypomethylation up-regulates CD147 expression through increasing Sp1 binding and associates with poor prognosis in human hepatocellular carcinoma. J Cell Mol Med 15: 1415-1428, 2011.
48. Zhang W, Zhou L, Ding SM, Xie HY, Xu X, Wu J, Chen QX, Zhang F, Wei BJ, Eldin AT and Zheng SS: Aberrant methylation of the CADM1 promoter is associated with poor prognosis in hepatocellular carcinoma treated with liver transplantation. Oncol Rep 25: 1053-1062, 2011.
49. Song MA, Tiirikainen M, Kwee S, Okimoto G, Yu H and Wong LL: Elucidating the landscape of aberrant DNA methylation in hepatocellular carcinoma. PLoS One 8: e55761, 2013.
50. Zhang YJ, Chen SY, Chen CJ and Santella RM: Polymorphisms in cyclin D1 gene and hepatocellular carcinoma. Mol Carcinog 33: 125-129, 2002.
51. 53 in hepatocellular carcinoma progression. J Hepatol 55: 724-725, 2011.
52. Stroescu C, Dragnea A, Ivanov B, Pechianu C, Herlea V, Sgarbura O, Popescu A and Popescu I: Expression of p53, Bcl-2, VEGF, Ki67 and PCNA and prognostic significance in hepatocellular carcinoma. J Gastrointestin Liver Dis 17: 411-417, 2008.
53. Laurent-Puig P and Zucman-Rossi J: Genetics of hepatocellular tumors. Oncogene 25: 3778-3786, 2006. (Pubitemid 43980473)
54. Frau M, Tomasi ML, Simile MM, Demartis MI, Salis F, Latte G, Calvisi DF, Seddaiu MA, Daino L, Feo CF, Brozzetti S, Solinas G, Yamashita S, Ushijima T, Feo F and Pascale RM: Role of transcriptional and posttranscriptional regulation of methionine adenosyltransferases in liver cancer progression. Hepatology 56: 165-175, 2012.
55. Huang YH, Lin KH, Chen HC, Chang ML, Hsu CW, Lai MW, Chen TC, Lee WC, Tseng YH and Yeh CT: Identification of postoperative prognostic microRNA predictors in hepatocellular carcinoma. PLoS One 7: e37188, 2012.
56. Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, Harris CC, Chen K, Hamilton SR and Zhang W: Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 6: e17745, 2011.
57. Liu XG, Zhu WY, Huang YY, Ma LN, Zhou SQ, Wang YK, Zeng F, Zhou JH and Zhang YK: High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol 29: 618-626, 2012.
58. Chen HY, Lin YM, Chung HC, Lang YD, Lin CJ, Huang J, Wang WC, Lin FM, Chen Z, Huang HD, Shyy JY, Liang JT and Chen RH: miR-103/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4. Cancer Res 72: 3631-3641, 2012.
59. Brenner B, Hoshen MB, Purim O, David MB, Ashkenazi K, Marshak G, Kundel Y, Brenner R, Morgenstern S, Halpern M, Rosenfeld N, Chajut A, Niv Y and Kushnir M: MicroRNAs as a potential prognostic factor in gastric cancer. World J Gastroenterol 17: 3976-3985, 2011.
60. Jamieson NB, Morran DC, Morton JP, Ali A, Dickson EJ, Carter CR, Sansom OJ, Evans TR, McKay CJ and Oien KA: MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin Cancer Res 18: 534-545, 2012.
61. Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK, Mutch DG, Grigsby PW, Powell SN and Wang X: A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol 114: 457-464, 2009.
62. Hiroki E, Akahira J, Suzuki F, Nagase S, Ito K, Suzuki T, Sasano H and Yaegashi N: Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci 101: 241-249, 2010.
63. Wang X, Wang J, Ma H, Zhang J and Zhou X: Downregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer. Med Oncol 29: 919-927, 2012.
64. Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G and Voros D: Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog 52: 297-303, 2013.
65. Yu J, Ohuchida K, Mizumoto K, Sato N, Kayashima T, Fujita H, Nakata K and Tanaka M: MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol Cancer 9: 169, 2010.
66. Wong KF, Xu Z, Chen J, Lee NP and Luk JM: Circulating markers for prognosis of hepatocellular carcinoma. Expert Opin Med Diagn 7: 319-329, 2013.
67. Anzola M: Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J Viral Hepat 11: 383-393, 2004.
68. Yao DF, Dong ZZ and Yao M: Specific molecular markers in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 6: 241-247, 2007.
69. Sharan R, Ulitsky I and Shamir R: Network-based prediction of protein function. Mol Syst Biol 3: 88, 2007.
70. Jenssen TK, Laegreid A, Komorowski J and Hovig E: A literature network of human genes for high-throughput analysis of gene expression. Nat Genet 28: 21-28, 2001. (Pubitemid 32405811)
71. Behm-Ansmant I, Rehwinkel J and Izaurralde E: MicroRNAs silence gene expression by repressing protein expression and/or by promoting mRNA decay. Cold Spring Harb Symp Quant Biol 71: 523-530, 2006.
72. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
73. Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell 11: 441-450, 2006. (Pubitemid 44430905)
74. Croce CM and Calin GA: miRNAs, cancer, and stem cell division. Cell 122: 6-7, 2005. (Pubitemid 40977933)
75. Tili E, Michaille JJ, Gandhi V, Plunkett W, Sampath D and Calin GA: miRNAs and their potential for use against cancer and other diseases. Future Oncol 3: 521-537, 2007 (Pubitemid 47595862)